{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:03:14Z","timestamp":1791352994230,"version":"4.3.1"},"reference-count":204,"publisher":"Elsevier BV","issue":"8","content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.tips.2013.05.009","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T06:16:43Z","timestamp":1371795403000},"page":"445-457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders"],"prefix":"10.1016","volume":"34","author":[{"given":"Mathias","family":"Buttmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srini","family":"Kaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2013.05.009_bib0005","first-page":"74","article-title":"[Therapy of multiple sclerosis with immunoglobulin G]","volume":"124","author":"Rothfelder","year":"1982","journal-title":"MMW Munch. Med. Wochenschr."},{"key":"10.1016\/j.tips.2013.05.009_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-510X(85)90173-X","article-title":"Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy","volume":"70","author":"Vermeulen","year":"1985","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang."},{"key":"10.1016\/j.tips.2013.05.009_bib0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1423-0410.2009.01217.x","article-title":"In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations","volume":"97","author":"Spycher","year":"2009","journal-title":"Vox Sang."},{"key":"10.1016\/j.tips.2013.05.009_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.vaccine.2004.06.023","article-title":"Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities","volume":"23","author":"Sastre","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.tips.2013.05.009_bib0030","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0140-6736(93)90563-V","article-title":"Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations","volume":"341","author":"Blasczyk","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.intimp.2005.11.003","article-title":"Differences between IGIV products: impact on clinical outcome","volume":"6","author":"Gelfand","year":"2006","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.tips.2013.05.009_bib0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","article-title":"Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies","volume":"231","author":"Lehmann","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0055","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF00918680","article-title":"Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies","volume":"11","author":"Liblau","year":"1991","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0060","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain\u2013Barr\u00e9 syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0065","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2013.05.009_bib0070","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0075","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/ana.410440610","article-title":"Neuromuscular blockade by IgG antibodies from patients with Guillain-Barr\u00e9 syndrome: a macro-patch-clamp study","volume":"44","author":"Buchwald","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0080","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1749-6632.1998.tb10999.x","article-title":"Neuromuscular blockade by immunoglobulin G from patients with Miller Fisher syndrome","volume":"841","author":"Buchwald","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0085","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awg235","article-title":"Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding","volume":"126","author":"Jacobs","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.tips.2013.05.009_bib0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410390121","article-title":"Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen","volume":"39","author":"Malik","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0100","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awh127","article-title":"Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies","volume":"127","author":"Zhang","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.tips.2013.05.009_bib0105","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.imlet.2012.01.005","article-title":"Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1","volume":"143","author":"Peng","year":"2012","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.tips.2013.05.009_bib0110","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1471-4159.2010.07029.x","article-title":"Antibodies against ganglioside complexes in Guillain\u2013Barr\u00e9 syndrome and related disorders","volume":"116","author":"Kusunoki","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tips.2013.05.009_bib0115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","article-title":"IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy","volume":"82","author":"Yuki","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0120","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jneuroim.2010.08.023","article-title":"IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN","volume":"229","author":"Piepers","year":"2010","journal-title":"J. Neuroimmunol."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2013.05.009_bib0125","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1007\/s10875-012-9752-6","article-title":"Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations","volume":"33","author":"Maddur","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cyto.2009.02.013","article-title":"Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins","volume":"46","author":"Tournadre","year":"2009","journal-title":"Cytokine"},{"key":"10.1016\/j.tips.2013.05.009_bib0135","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaci.2010.12.1102","article-title":"Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin","volume":"127","author":"Maddur","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4614-3461-0_10","article-title":"Modulation of dendritic cells and regulatory T cells by naturally occurring antibodies","volume":"750","author":"Kwekkeboom","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tips.2013.05.009_bib0145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3899\/jrheum.111123","article-title":"Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease","volume":"39","author":"Bayry","year":"2012","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.tips.2013.05.009_bib0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10875-012-9816-7","article-title":"Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells","volume":"33","author":"Costa","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0155","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2012.08.017","article-title":"Tregitope update: mechanism of action parallels IVIg","volume":"12","author":"Cousens","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0160","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0165","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood.V100.5.1774.h81702001774_1774_1779","article-title":"Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis","volume":"100","author":"Mouzaki","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.tips.2013.05.009_bib0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1600-0897.2003.01169.x","article-title":"Effect of intravenous immunoglobulin treatment on the Th1\/Th2 balance in women with recurrent spontaneous abortions","volume":"49","author":"Graphou","year":"2003","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0175","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tips.2013.05.009_bib0180","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood-2012-07-445007","article-title":"Intravenous immunoglobulin (IVIg) inhibits CD8 cytotoxic T-cell activation","volume":"120","author":"Trepanier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tips.2013.05.009_bib0185","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0b013e31827debad","article-title":"Recovery of the T-cell repertoire in CIDP by IV immunoglobulins","volume":"80","author":"Mausberg","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.imlet.2012.12.011","article-title":"IVIg prevents the in vitro activation of T cells by neutralizing the T cell activators","volume":"150","author":"Padet","year":"2013","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.tips.2013.05.009_bib0195","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1172\/JCI118488","article-title":"Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use","volume":"97","author":"Kaveri","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tips.2013.05.009_bib0200","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","article-title":"Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain","volume":"89","author":"Marchalonis","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.05.009_bib0205","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2249.2011.04476.x","article-title":"Neutralization of mitogenic lectins by intravenous immunoglobulin (IVIg) prevents T cell activation: does IVIg really have a direct effect on T cells?","volume":"166","author":"Padet","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0210","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(01)00243-0","article-title":"Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis","volume":"114","author":"Aktas","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0215","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.4049\/jimmunol.1201965","article-title":"Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1\u2013mammalian target of rapamycin axis","volume":"190","author":"Othy","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0220","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1002\/jcp.24100","article-title":"\u03b1M\u03b22-Integrin\u2013intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain\u2013Barr\u00e9 syndrome patient derived mononuclear leukocytes at the blood\u2013nerve barrier in vitro","volume":"227","author":"Yosef","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tips.2013.05.009_bib0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-5728(02)00430-7","article-title":"Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte Fc\u03b3RII expression in patients with chronic inflammatory neuropathies","volume":"135","author":"Creange","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0230","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.52.9.1833","article-title":"IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain\u2013Barr\u00e9 syndrome","volume":"52","author":"Sharief","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0235","first-page":"487","article-title":"Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain\u2013Barr\u00e9 syndrome","volume":"51","author":"Reuben","year":"2003","journal-title":"Neurol. India"},{"key":"10.1016\/j.tips.2013.05.009_bib0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1399-3038.2008.00789.x","article-title":"Increased blood plasma concentrations of TGF-\u03b21 and TGF-\u03b22 after treatment with intravenous immunoglobulins in childhood autoimmune diseases","volume":"20","author":"Rissmann","year":"2009","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0245","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.03.018","article-title":"Increased blood plasma concentrations of TGF-\u03b2 isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis","volume":"152","author":"Reinhold","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0250","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1182\/blood.V91.6.2054","article-title":"Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations","volume":"91","author":"Svenson","year":"1998","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2013.05.009_bib0255","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/s10875-010-9398-1","article-title":"Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy","volume":"30","author":"Tackenberg","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0260","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jneuroim.2013.01.001","article-title":"Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy \u2013 a new mechanism of action?","volume":"256","author":"Bick","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-3083.1994.tb03430.x","article-title":"Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca2+-dependent signal transduction through Fc gamma receptors in B lymphocytes","volume":"40","author":"Kondo","year":"1994","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s10875-010-9469-3","article-title":"IVIg attenuates TLR-9 activation in B cells from SLE patients","volume":"31","author":"Kessel","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0275","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1034\/j.1600-6143.2003.00011.x","article-title":"Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells","volume":"3","author":"Toyoda","year":"2003","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.tips.2013.05.009_bib0280","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.161.7.3781","article-title":"Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway","volume":"161","author":"Prasad","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0285","doi-asserted-by":"crossref","first-page":"e2109","DOI":"10.1371\/journal.pone.0002109","article-title":"Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain\u2013Barr\u00e9 syndrome","volume":"3","author":"Mori","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tips.2013.05.009_bib0290","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.tips.2013.05.009_bib0295","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1002\/art.11346","article-title":"Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-\u03b1 present in serum from patients with systemic lupus erythematosus","volume":"48","author":"Bayry","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2013.05.009_bib0300","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaut.2012.05.013","article-title":"Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: role of lipid accumulation","volume":"39","author":"Othy","year":"2012","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.tips.2013.05.009_bib0305","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood-2009-06-225417","article-title":"Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation","volume":"115","author":"Aubin","year":"2010","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2013.05.009_bib0310","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1538-7836.2009.03420.x","article-title":"New insight into the mechanism of action of IVIg: the role of dendritic cells","volume":"7","author":"Crow","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.tips.2013.05.009_bib0315","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0165-0378(96)00969-2","article-title":"Effect of intravenous immunoglobulin G on natural killer cell cytotoxicity in vitro in women with recurrent spontaneous abortion","volume":"31","author":"Ruiz","year":"1996","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0320","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.clim.2009.09.006","article-title":"Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity","volume":"133","author":"Jacobi","year":"2009","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0325","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000084301","article-title":"CD16+CD57\u2212 natural killer cells in multifocal motor neuropathy","volume":"53","author":"Mizutani","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0330","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00024382-199904000-00011","article-title":"Effect of intravenous immunoglobulin G on the TNF\u03b1-mediated hepatic microvascular inflammatory response","volume":"11","author":"Ito","year":"1999","journal-title":"Shock"},{"key":"10.1016\/j.tips.2013.05.009_bib0335","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2249.2004.02496.x","article-title":"Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells","volume":"137","author":"Radder","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0340","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.imbio.2006.02.003","article-title":"Effects of intravenous immunoglobulin and methylprednisolone on human umbilical vein endothelial cells in vitro","volume":"211","author":"Yoon","year":"2006","journal-title":"Immunobiology"},{"key":"10.1016\/j.tips.2013.05.009_bib0345","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0002-9440(10)65670-2","article-title":"Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases","volume":"153","author":"Xu","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tips.2013.05.009_bib0350","first-page":"1046","article-title":"Therapeutic immunoglobulin reduces Ca2+ mobilization and von Willebrand factor secretion, and increases nitric oxide release in human endothelial cells","volume":"90","author":"David-Dufilho","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.tips.2013.05.009_bib0355","doi-asserted-by":"crossref","first-page":"26473","DOI":"10.1074\/jbc.271.43.26473","article-title":"Human immunoglobulins inhibit thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells","volume":"271","author":"Schussler","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2013.05.009_bib0360","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00011-004-1255-3","article-title":"An immunoglobulin agent (IVIG) inhibits NF-\u03baB activation in cultured endothelial cells of coronary arteries in vitro","volume":"53","author":"Ichiyama","year":"2004","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.tips.2013.05.009_bib0365","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain\u2013Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0370","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain\u2013Barr\u00e9 syndrome","volume":"83","author":"Rajabally","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0375","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMra1114525","article-title":"Guillain\u2013Barr\u00e9 syndrome","volume":"366","author":"Yuki","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2013.05.009_bib0380","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.expneurol.2012.03.023","article-title":"A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies","volume":"235","author":"Uncini","year":"2012","journal-title":"Exp. Neurol."},{"issue":"Suppl. 3","key":"10.1016\/j.tips.2013.05.009_bib0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1529-8027.2012.00433.x","article-title":"Recent developments and future directions in Guillain\u2013Barr\u00e9 syndrome","volume":"17","author":"Lehmann","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0390","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneuro0452","article-title":"From bench to bedside \u2013 experimental rationale for immune-specific therapies in the inflamed peripheral nerve","volume":"3","author":"Meyer zu Horste","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0395","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain\u2013Barr\u00e9 syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tips.2013.05.009_bib0400","first-page":"CD001446","article-title":"Corticosteroids for Guillain\u2013Barr\u00e9 syndrome","volume":"8","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-4886(85)90129-3","article-title":"Effects of glucocorticoids on experimental allergic neuritis","volume":"87","author":"King","year":"1985","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-4886(89)90191-X","article-title":"High-dose methylprednisolone suppresses experimental allergic neuritis in the Lewis rat","volume":"103","author":"Watts","year":"1989","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0415","first-page":"CD001798","article-title":"Plasma exchange for Guillain\u2013Barr\u00e9 syndrome","volume":"7","author":"Raphael","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0420","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1212\/WNL.0b013e318207b1f6","article-title":"Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"76","author":"Cortese","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0425","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/WCO.0b013e32830b0f61","article-title":"Plasma exchange in immune-mediated neuropathies","volume":"21","author":"Lehmann","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0430","first-page":"719","article-title":"[Initial experiences in the use of intravenous immunoglobulins in Guillain\u2013Barr\u00e9\u2013Strohl syndrome]","volume":"9","author":"Ceccarelli","year":"1987","journal-title":"Pediatr. Med. Chir."},{"key":"10.1016\/j.tips.2013.05.009_bib0435","first-page":"731","article-title":"[A case of Guillain\u2013Barr\u00e9 syndrome treated with intravenous high doses of immunoglobulins]","volume":"145","author":"Mauro","year":"1989","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0440","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.38.10.1639","article-title":"Treatment of Guillain\u2013Barr\u00e9 syndrome with high-dose gammaglobulin","volume":"38","author":"Kleyweg","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0445","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain\u2013Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0450","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain\u2013Barr\u00e9 syndrome","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0455","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain\u2013Barr\u00e9 syndrome","volume":"326","author":"van der Meche","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2013.05.009_bib0460","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain\u2013Barr\u00e9 syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0465","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1744-9987.1998.tb00124.x","article-title":"Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report","volume":"2","author":"Hosokawa","year":"1998","journal-title":"Ther. Apher."},{"key":"10.1016\/j.tips.2013.05.009_bib0470","first-page":"69","article-title":"A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain\u2013Barr\u00e9 syndrome","volume":"18","author":"Nomura","year":"2001","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.tips.2013.05.009_bib0475","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome","volume":"7","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0480","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0485","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0490","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain\u2013Barr\u00e9 syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0495","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/brain\/118.4.841","article-title":"Guillain\u2013Barr\u00e9 syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features","volume":"118","author":"Visser","year":"1995","journal-title":"Brain"},{"key":"10.1016\/j.tips.2013.05.009_bib0500","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C","article-title":"Clinical features and response to treatment in Guillain\u2013Barr\u00e9 syndrome associated with antibodies to GM1b ganglioside","volume":"47","author":"Yuki","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0505","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","article-title":"Campylobacter jejuni infections and anti-GM1 antibodies in Guillain\u2013Barr\u00e9 syndrome","volume":"40","author":"Jacobs","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0510","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.tips.2013.05.009_bib0515","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2013Barr\u00e9 syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2013.05.009_bib0520","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1007\/s10875-010-9407-4","article-title":"IVIG treatment and prognosis in Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2010","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0525","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0530","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"352","author":"K\u00f6ller","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.tips.2013.05.009_bib0535","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1529-8027.2012.00393.x","article-title":"Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies","volume":"17","author":"Dalakas","year":"2012","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib1025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/WNL.41.5.617","article-title":"Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force","volume":"41","author":"Cornblath","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0545","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/mus.22038","article-title":"Review of the evolution of electrodiagnostic criteria for chronic inflammatory demyelinating polyradicoloneuropathy","volume":"43","author":"Bromberg","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1529-8027.2010.00245.x","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0555","first-page":"CD002062","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"8","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0560","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0565","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.0b013e31824e8f84","article-title":"Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment","volume":"78","author":"Eftimov","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0570","first-page":"CD003280","article-title":"Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"11","author":"Mahdi-Rogers","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0575","first-page":"CD003906","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"9","author":"Mehndiratta","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0580","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0585","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0590","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","article-title":"High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study","volume":"40","author":"van Doorn","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0595","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00868527","article-title":"A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"243","author":"Thompson","year":"1996","journal-title":"J. Neurol."},{"issue":"Pt 4","key":"10.1016\/j.tips.2013.05.009_bib0600","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.tips.2013.05.009_bib0605","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2","author":"Van Schaik","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0610","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0615","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0620","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0625","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneurol.2010.105","article-title":"Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Latov","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0630","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archneurol.2010.223","article-title":"Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Donofrio","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0635","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mus.21733","article-title":"Electrophysiologic correlations with clinical outcomes in CIDP","volume":"42","author":"Bril","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0640","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mus.21236","article-title":"Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV","volume":"39","author":"Bril","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0645","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","article-title":"Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study","volume":"72","author":"Merkies","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0650","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1085-9489.2006.00059.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society","volume":"11","author":"Joint Task Force of the EFNS and the PNS","year":"2006","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0655","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0660","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1529-8027.2011.00340.x","article-title":"The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin","volume":"16","author":"Cocito","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0665","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0670","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","article-title":"Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies","volume":"253","author":"K\u00f6ller","year":"2006","journal-title":"J. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0675","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0b013e3181bd1139","article-title":"Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP","volume":"73","author":"Iijima","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0680","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mus.880110203","article-title":"Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease","volume":"11","author":"Parry","year":"1988","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0685","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1097-4598(199802)21:2<243::AID-MUS14>3.0.CO;2-2","article-title":"Multifocal motor neuropathy without overt conduction block","volume":"21","author":"Pakiam","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0690","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1136\/jnnp.2005.064816","article-title":"Axon loss is an important determinant of weakness in multifocal motor neuropathy","volume":"77","author":"Van Asseldonk","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0695","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jocn.2012.02.011","article-title":"Multifocal motor neuropathy","volume":"19","author":"Muley","year":"2012","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.tips.2013.05.009_bib0700","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100028894","article-title":"Neuropathy with onion bulb formations and pure motor manifestations","volume":"16","author":"Auer","year":"1989","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0705","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ana.410330204","article-title":"Pathological findings at the site of conduction block in multifocal motor neuropathy","volume":"33","author":"Kaji","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0710","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/mus.880170117","article-title":"Anti-GM1 antibodies and impaired blood\u2013nerve barrier may interfere with remyelination in multifocal motor neuropathy","volume":"17","author":"Kaji","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib0715","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/jnen\/63.2.129","article-title":"Multifocal motor neuropathy: pathologic alterations at the site of conduction block","volume":"63","author":"Taylor","year":"2004","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0720","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1529-8027.2010.00290.x","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0725","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"Van den Berg","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0730","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0735","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.tips.2013.05.009_bib0740","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0745","first-page":"CD004429","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"2","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0750","first-page":"1214","article-title":"[Motor-dominant neuropathy with multifocal conduction block]","volume":"30","author":"Sonoo","year":"1990","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.tips.2013.05.009_bib0755","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/0140-6736(92)93339-O","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"340","author":"Kermode","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0760","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0765","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0770","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10072-010-0352-z","article-title":"Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report","volume":"31","author":"Dacci","year":"2010","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0775","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0780","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.tips.2013.05.009_bib0785","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.57.7.778","article-title":"Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin","volume":"57","author":"Donaghy","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.tips.2013.05.009_bib0790","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.50.5.1480","article-title":"Deterioration of multifocal motor neuropathy after plasma exchange","volume":"50","author":"Carpo","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0795","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jns.2008.02.022","article-title":"The clinical value of therapeutic plasma exchange in multifocal motor neuropathy","volume":"271","author":"Lehmann","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0800","first-page":"CD003217","article-title":"Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy","volume":"4","author":"Umapathi","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0805","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.tips.2013.05.009_bib0810","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0815","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ncl.2010.12.005","article-title":"Definitions of breakthrough disease and second-line agents","volume":"29","author":"Marriott","year":"2011","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.tips.2013.05.009_bib0820","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.tips.2013.05.009_bib0825","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1586\/ern.10.38","article-title":"Treating multiple sclerosis with monoclonal antibodies: a 2010 update","volume":"10","author":"Buttmann","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.tips.2013.05.009_bib0830","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/ern.11.15","article-title":"Principles of a new treatment algorithm in multiple sclerosis","volume":"11","author":"Hartung","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.tips.2013.05.009_bib0835","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/ern.13.17","article-title":"Treating multiple sclerosis with monoclonal antibodies: a 2013 update","volume":"13","author":"Deiss","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.tips.2013.05.009_bib0840","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","article-title":"Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0845","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","article-title":"Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review","volume":"79","author":"Lu","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0850","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000115560","article-title":"First results of immunotherapy with immunoglobulin G in multiple sclerosis patients","volume":"22","author":"Schuller","year":"1983","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0855","first-page":"477","article-title":"[Gamma globulin therapy in multiple sclerosis. Theoretical considerations and initial clinical experiences with 7S immunoglobulins in MS therapy]","volume":"136","author":"Soukop","year":"1986","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.tips.2013.05.009_bib0860","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/0140-6736(90)92188-N","article-title":"High-dose intravenous immunoglobulin for multiple sclerosis","volume":"336","author":"Yan","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0865","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archneur.1992.00530360031013","article-title":"Open controlled therapeutic trial of intravenous immune globulin in relapsing\u2013remitting multiple sclerosis","volume":"49","author":"Achiron","year":"1992","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0870","first-page":"CD002936","article-title":"Intravenous immunoglobulins for multiple sclerosis","volume":"4","author":"Gray","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2013.05.009_bib0875","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jns.2006.12.018","article-title":"Intravenous immunoglobulin in MS: promise or failure?","volume":"259","author":"Fazekas","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib0880","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1468-1331.2002.00500.x","article-title":"No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment","volume":"9","author":"Lewanska","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0885","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0890","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing\u2013remitting multiple sclerosis","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0895","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s002340000444","article-title":"Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report","volume":"42","author":"Teksam","year":"2000","journal-title":"Neuroradiology"},{"key":"10.1016\/j.tips.2013.05.009_bib0900","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.50.5.1273","article-title":"Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis","volume":"50","author":"Sorensen","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0905","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing\u2013remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0910","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.0b013e3181ab6b81","article-title":"Intravenous immunoglobulin in relapsing\u2013remitting multiple sclerosis: a dose-finding trial","volume":"73","author":"Engel","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0915","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1212\/01.wnl.0000349656.65459.5f","article-title":"Intravenous immunoglobulin in relapsing\u2013remitting multiple sclerosis: a dose-finding trial","volume":"72","author":"Khan","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0920","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0925","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00415-004-0495-z","article-title":"Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis","volume":"251","author":"Achiron","year":"2004","journal-title":"J. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0930","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1177\/1352458506075654","article-title":"A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis","volume":"13","author":"Haas","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2013.05.009_bib0935","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1756285608100416","article-title":"Immunomodulation and postpartum relapses in patients with multiple sclerosis","volume":"2","author":"Hellwig","year":"2009","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.tips.2013.05.009_bib0940","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1468-1331.2008.02258.x","article-title":"Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin","volume":"15","author":"Tselis","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0945","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","article-title":"IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS","volume":"63","author":"Sorensen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0950","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","article-title":"A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis","volume":"64","author":"Roed","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0955","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0960","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","article-title":"IV immunoglobulin does not reverse established weakness in MS","volume":"55","author":"Noseworthy","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib0965","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(04)17101-8","article-title":"Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial","volume":"364","author":"Hommes","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2013.05.009_bib0970","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1352458507078400","article-title":"Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study","volume":"13","author":"P\u00f6hlau","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.tips.2013.05.009_bib0975","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0980","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/S0004-282X2012000100012","article-title":"Treatment of neuromyelitis optica: an evidence based review","volume":"70","author":"Sato","year":"2012","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.tips.2013.05.009_bib0985","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.tips.2013.05.009_bib0990","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.tips.2013.05.009_bib0995","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2169\/internalmedicine.46.0217","article-title":"Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica","volume":"46","author":"Okada","year":"2007","journal-title":"Intern. Med."},{"key":"10.1016\/j.tips.2013.05.009_bib1000","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","article-title":"Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)","volume":"31","author":"Bakker","year":"2004","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.tips.2013.05.009_bib1005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P04.141","article-title":"Treatment of neuromyelitis optica with intravenous immunoglobulin: report of 8 patients","volume":"78","author":"Bichuetti","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2013.05.009_bib1010","series-title":"Abstracts of the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis","first-page":"735","article-title":"Neuromyelitis optica in pregnancy: treatment with intravenous immunoglobulin","author":"Houtchens","year":"2012"},{"key":"10.1016\/j.tips.2013.05.009_bib1015","first-page":"601","article-title":"[Senile-onset recurrent myelitis with anti-aquaporin-4 antibody]","volume":"61","author":"Nakano","year":"2009","journal-title":"Brain Nerve"},{"key":"10.1016\/j.tips.2013.05.009_bib1020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00296-008-0611-y","article-title":"Reversible stenosis of large cerebral arteries in a patient with combined Sjogren's syndrome and neuromyelitis optica spectrum disorder","volume":"28","author":"Ii","year":"2008","journal-title":"Rheumatol. Int."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614713000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T14:09:03Z","timestamp":1688306943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614713000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":204,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0165614713000977"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2013.05.009","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2013.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}